Unlocking Opportunities in the Rheumatology Therapeutics Market: 2025-2034 Forecast Report

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Rheumatology Therapeutics Industry Market Size Be by 2025?
In recent years, the rheumatology therapeutics market dimensions have seen consistent growth. Predicted to rise from $42.4 billion in 2024 to $44.18 billion in 2025, this represents a compound annual growth rate (CAGR) of 4.2%. This growth during the historic period is attributed to factors such as an increase in rheumatologic disorder cases, a growing global elderly population, heightened awareness around treatment alternatives, advancements in biological therapies, as well as an expansion of accessibility to healthcare in emerging markets.

What's the Long-Term Growth Forecast for the Rheumatology Therapeutics Market Size Through 2029?
In the coming years, the size of the rheumatology therapeutics market is predicted to experience a consistent expansion, reaching "$52.25 billion in 2029 with a compound annual growth rate (CAGR) of 4.3%. The predicted growth within the forecast window can be credited to factors like the transition towards personalized treatments, an increased acceptance of biosimilars in rheumatology, more investments in research and developments, the incorporation of digital health technology, and the sanctioning of new treatment methods. Notable trends in the forecasted period include the development in telemedicine and remote patient monitoring systems, the spread of targeted treatments for specific rheumatic diseases, a focus on patient-driven care models, the expansion of biologic treatments beyond monoclonal antibodies, and the implementation of value-based pricing strategies.

View the full report here:
https://www.thebusinessresearchcompany.com/report/rheumatology-therapeutics-global-market-report

What Are the Key Growth Drivers Fueling the Rheumatology Therapeutics Market Expansion?
An increase in the incidence of autoimmune diseases is projected to drive the expansion of the rheumatology therapeutics market. Autoimmune diseases are conditions in which the immune system mistakenly attacks the body's own tissues. Genetic, environmental, and lifestyle influences, along with improved diagnostic capabilities and heightened awareness, are contributing to the rising prevalence of these diseases. Rheumatology therapeutics are essential for managing inflammation, controlling symptoms, and minimizing joint and tissue damage caused by the immune system's assault on the body. For example, data from the Australian Institute of Health and Welfare in June 2024 indicated that approximately 514,000 Australians, or 2.0% of the population, were living with rheumatoid arthritis in 2022. Rheumatoid arthritis represented 2.0% of the total disease burden and 16% of the burden of all musculoskeletal conditions in 2023. As such, the increasing incidence of autoimmune diseases is accelerating the growth of the rheumatology therapeutics market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=17246&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Rheumatology Therapeutics Market?
Prominent corporations in the rheumatology therapeutics market are pioneering novel solutions such as intravenous (IV) formulations to augment treatment effectiveness and patient ease. The term intravenous (IV) formulation refers to a drug or substance being directly delivered into a vein via a needle or catheter. Case in point, in October 2023, the US Food and Drug Administration approved Cosentyx, an intravenous (IV) formulation by Novartis AG, a pharmaceutical firm based in Switzerland. This version of Cosentyx is distinctively approved for treating adults suffering from psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA). The drug functions by specifically counteracting and restraining interleukin-17A (IL-17A) and is the sole non-tumor necrosis factor alpha (TNF-α) IV treatment accessible for these conditions.

How Is the Rheumatology Therapeutics Market Segmented?
The rheumatology therapeutics market covered in this report is segmented -

1) By Drug Class: Disease Modifying Anti-Rheumatic Drugs, Nonsteroidal Anti-Inflammatory Drugs, Corticosteroids, Uric Acid Drugs, Other Drugs Classes
2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
3) By Disease Indication: Rheumatoid Arthritis, Osteoarthritis, Gout, Psoriatic Arthritis, Ankylosing Spondylitis, Other Disease Indications

Subsegments:
1) By Disease Modifying Anti-Rheumatic Drugs (DMARDs): Conventional Synthetic DMARDs, Biologic DMARDs, Targeted Synthetic DMARDs
2) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): COX-2 Inhibitors, Traditional NSAIDs
3) By Corticosteroids: Oral Corticosteroids, Injectable Corticosteroids, Topical Corticosteroids
4) By Uric Acid Drugs: Uric Acid Lowering Agents, Uricosuric Agents, Pegloticase
5) By Other Drug Classes: Immunosuppressants, Biologic Therapies, Analgesics

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=17246&type=smp

Which Companies Are Leading the Charge in Rheumatology Therapeutics Market Innovation?
Major companies operating in the rheumatology therapeutics market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Janssen Biotech, Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals, UCB S.A., Galapagos NV (GLPG), Genentech Inc.

Which Regions Are Leading the Global Rheumatology Therapeutics Market in Revenue?
North America was the largest region in the rheumatology therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rheumatology therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=17246

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.